Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
MENLO PARK, Calif., April 05, 2016 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its First Quarter 2016 Financial Results on Thursday, April 21, 2016, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: April 21, 2016
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences Trevin Rard 650.521.8450 [email protected]
